A dual-functional microfluidic chip for guiding personalized lung cancer medicine: combining EGFR mutation detection and organoid-based drug response test-Reference-Cited by-同舟云学术

A dual-functional microfluidic chip for guiding personalized lung cancer medicine: combining EGFR mutation detection and organoid-based drug response test

Published:2024 Issue:6 Volume:24 Page:1762-1774
ISSN:1473-0197
Container-title:Lab on a Chip
language:en
Short-container-title:Lab Chip

Author:

Zhang Kexin¹,Xi Jiyu¹,Zhao Huiting¹^ORCID,Wang Yadong²³,Xue Jianchao²³,Liang Naixin²,Wei Zewen¹^ORCID

Affiliation:

1. Department of Biomedical Engineering, School of Medical Technology, Beijing Institute of Technology, Beijing 100081, China

2. Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China

3. Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China

Abstract

The RDMO-Chip combines rapid EGFR mutation detection and organoid-based drug response test for guiding personalized lung cancer medicine.

Funder

National Natural Science Foundation of China

National Key Laboratory of Science and Technology on Micro/Nano Fabrication

Beijing Institute of Technology Research Fund Program for Young Scholars

Publisher

Royal Society of Chemistry (RSC)

Link

http://pubs.rsc.org/en/content/articlepdf/2024/LC/D3LC00974B

Reference54 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

3. Increased demand for NAD+ relative to ATP drives aerobic glycolysis

4. Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship

5. Non-Small Cell Lung Cancer Metastatic, https://www.nccn.org/patients/guidelines/content/PDF/lung-metastatic-patient.pdf